Hans E. Geisler

The use of megestrol acetate in the treatment of advanced malignant lesions of the endometrium

Abstract The use of megestrol acetate, an oral progestin, was evaluated in a group of patients with far advanced, endometrial carcinoma. Using strict criteria, over 40% of the patients achieved an objective remission at doses ranging from 80 to 160 mg per day.

Tumor markers and molecular biological markers in gynecologic malignancies.

Gynecologic oncology is a rapidly growing field due to constant advances in immunohistochemistry and molecular biology. This review serves as an overview of new studies promoting the use of tumor markers and molecular biological prognostic factors in malignancies affecting women. The majority of studies focus on either endometrial or ovarian carcinoma. Other gynecologic malignancies (cervical, vulvar, and vaginal carcinoma) have a much smaller representation in the world literature. Multiple new markers were examined over the last year. We conclude that although some markers show promise as potential new consensus prognostic indicators, more work is needed to confirm results and clarify any existing discrepancies.

Treatment of advanced, unresectable, cervical carcinoma already subjected to complete irradiation therapy

Abstract Thirty-seven patients with unresectable, previously irradiated, epidermoid carcinoma of the cervix were treated with one of three chemotherapy protocols: (i) moderate dose methotrexate, (ii) high dose methotrexate, and (iii) adriamycin. The choice of chemotherapeutic agent was based on renal and hepatic function. Antineoplastic effect was followed by physical and pelvic examinations, X rays, and scans. Review of the data of patients treated over a period of 3 years demonstrated a clinical response in all three categories. Of interest is the fact that moderate dose methotrexate was the most effective protocol and was well tolerated.

The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide

Abstract Twenty-six patients with Stage III or IV ovarian carcinoma have been treated with high dose, intravenous, pulsatile cyclophosphamide. An initial objective response of 88% has been achieved. Several patients who have had second look operations have been free of disease at that time and have remained so.

DNA index by image analysis in advanced endometrial carcinoma

Endometrial carcinoma is the most common gynecologic malignancy in developed countries, affecting an estimated 140,000 women. More than 32,000 women will be diagnosed with endometrial cancer this year in the United States, and approximately 6,000 will die from this disease.